查看文章

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide and new drugs were licensed for its treatment. Quite a few studies worked on spectrum of respiratory side effects associated with those new therapies. This work aimed to evaluate respiratory side effects associated with sofosbuvir-based regimens used for treatment of chronic HCV.

This study included 418 patients with HCV infection classified into 3 groups according to the treatment regimen: Group 1 (IFN-Sof-Rib): received triple therapy of sofosbuvir, pegylated interferon (Peg IFN)-α and ribavirin for 12 weeks. Group 2 (Sof-Rib): received combined therapy of sofosbuvir, and ribavirin for 24 weeks, and Group 3 (Sof-Dacl-Rib): received triple therapy of sofosbuvir, daclatasvir and ribavirin for 12 weeks. All patients underwent baseline assessment including history taking, clinical examination, routine …